« Back
Home /
GGFG-PAB-MMAE

GGFG-PAB-MMAE

Item no.	HY-164788-5mg
Manufacturer	MedChem Express
CASRN	3049886-19-0
Amount	5 mg
Quantity options	1 ea 5 mg
Category	Reagents & Chemicals Ligands & Crosslinkers Crosslinkers
Type	Crosslinkers
Specific against	other
Purity	99.27
Citations	[1]Jinkun Huang, et al. Highly stable targeted linker-drug conjugate. US20240293570A1.
Smiles	O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC(CNC([C@@H](NC(CNC(CN)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)=O)OC)=O
ECLASS 10.1	32170205
ECLASS 11.0	32170205
UNSPSC	41105316
Shipping Condition	Cool pack
Available
Manufacturer - Type	ADC Related
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Drug-Linker Conjugates for ADC; Microtubule/Tubulin
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	1185.45
Product Description	GGFG-PAB-MMAE (Comp 58054-1) is a drug-linker conjugate for ADC. GGFG-PAB-MMAE contains the ADC linker (GGFG-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162)[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 120 mg/mL (ultrasonic)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Isoform	Auristatin
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question